PT - JOURNAL ARTICLE AU - Nol Salcedo AU - Nidhi Nandu AU - Julie Boucau AU - Bobby Brooke Herrera TI - Detection of SARS-CoV-2 Omicron, Delta, Alpha and Gamma variants using a rapid antigen test AID - 10.1101/2022.01.27.22269299 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.27.22269299 4099 - http://medrxiv.org/content/early/2022/01/27/2022.01.27.22269299.short 4100 - http://medrxiv.org/content/early/2022/01/27/2022.01.27.22269299.full AB - Throughout the coronavirus disease 2019 (COVID-19) pandemic, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have emerged with different infection and disease dynamics. Testing strategies, including clinical diagnosis, surveillance, and screening, have been deployed to help limit the spread of SARS-CoV-2 variants. Rapid antigen tests, in particular, have been approved for self-testing in many countries and governments are supporting their manufacturing and distribution. However, studies demonstrating the accuracy of rapid antigen tests in detecting SARS-CoV-2 variants, especially the new Omicron variant, are limited. We determined the analytical sensitivity of a CE-marked rapid antigen test against the Omicron, Delta, Alpha and Gamma variants. The rapid antigen test had the most sensitive limit of detection (10 plaque forming units [PFU]/mL) when tested with the Alpha and Gamma variants, followed by the Omicron (100 PFU/mL) and Delta (1,000 PFU/mL) variants. Given the increasing numbers of breakthrough infections and the need to surveil infectiousness, rapid antigen tests are effective public health tools to detect SARS-CoV-2 variants.Competing Interest StatementNS, NN, and BBH are employed by E25Bio, Inc., a biotechnology company that develops diagnostic assays for infectious diseases.Funding StatementThe authors declare that this study received funding from E25Bio, Inc. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. The MassCPR variants repository is funded by the Massachusetts Consortium on Pathogen Readiness. The Ragon BSL3 is partially supported by the Harvard Center for AIDS Research, a National Institutes of Health funded program [P30AI060354] and the Massachusetts Consortium on Pathogen Readiness.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The collection of isolates was approved by the Massachusetts General Hospital Institutional Review Board (approval number 2019P003305).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors